Trial Profile

A Two-part, Open-label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 in Combination With Low-dose Subcutaneous Interleukin-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary) ; ICT 01 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Ovarian cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Acronyms EVICTION-2
Sponsors ImCheck Therapeutics

24 Dec 2025 Status changed from active, no longer recruiting to completed.
31 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Sep 2025.
28 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com